Gallic acid suppresses inflammation in dextran sodium sulfate-induced colitis in mice: Possible mechanisms

International Immunopharmacology

Volumn 28, Issue 2, 2015, Pages 1034-1043

  Pandurangan, Ashok Kumar ^a,b   Mohebali, Nooshin ^b   Esa, Norhaizan Mohd ^a   Looi, Chung Yeng ^b   Ismail, Salmiah ^a   Saadatdoust, Zeinab ^a  

^a UNIVERSITY PUTRA MALAYSIA   (Malaysia)

^b UNIVERSITY OF MALAYA   (Malaysia)

Author keywords

Gallic acid; Inflammatory bowel disease; NF B; STAT3; Ulcerative colitis

Indexed keywords

CD68 ANTIGEN; CYCLOOXYGENASE 2; CYTOKINE; GALLIC ACID; GAMMA INTERFERON; I KAPPA B; INDUCIBLE NITRIC OXIDE SYNTHASE; INTERLEUKIN 17; INTERLEUKIN 1BETA; INTERLEUKIN 6; MYELOPEROXIDASE; STAT3 PROTEIN; TRANSCRIPTION FACTOR RELA; TUMOR NECROSIS FACTOR ALPHA; AUTACOID; DEXTRAN SULFATE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; IMMUNOSUPPRESSIVE AGENT; PTGS2 PROTEIN, MOUSE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; COLON MUCOSA; CONTROLLED STUDY; DEXTRAN SODIUM SULFATE-INDUCED COLITIS; DRUG MECHANISM; ENZYME ACTIVITY; MALE; MOUSE; NONHUMAN; NUCLEAR LOCALIZATION SIGNAL; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; ULCERATIVE COLITIS; ANIMAL; BAGG ALBINO MOUSE; CHEMICALLY INDUCED; COLITIS; DISEASE MODEL; DRUG EFFECTS; HUMAN; IMMUNOLOGY; INFLAMMATORY BOWEL DISEASES; INTESTINE MUCOSA; METABOLISM;

ANIMALS; COLITIS; CYCLOOXYGENASE 2; CYTOKINES; DEXTRAN SULFATE; DISEASE MODELS, ANIMAL; GALLIC ACID; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INFLAMMATION MEDIATORS; INFLAMMATORY BOWEL DISEASES; INTESTINAL MUCOSA; MALE; MICE; MICE, INBRED BALB C; NF-KAPPA B; NITRIC OXIDE SYNTHASE TYPE II; STAT3 TRANSCRIPTION FACTOR;

EID: 84940099920     PISSN: 15675769     EISSN: 18781705     Source Type: Journal    
DOI: 10.1016/j.intimp.2015.08.019     Document Type: Article

References (49)

1. N.A. Molodecky, S. Soon, D.M. Rabi, W.A. Ghali, M. Ferris, G. Chernoff, et al., Increasing incidence and prevalence of the inflammatory bowel diseases with time, based on systematic review, Gastroenterology 142 (2012) 46-54 (e42).
2. S. Ardizzone, G.B. Porro, Biologic therapy for inflammatory bowel disease, Drugs 65 (2005) 2253-2286.
3. T.J. Slebioda, Z. Kmieć, Tumour necrosis factor superfamily members in the pathogenesis of inflammatory bowel disease, Mediat. Inflamm. 2014 (2014).
4. A.K. Pandurangan, N.M. Esa, Signal transducer and activator of transcription 3-A promising target in colitis-Associated cancer, Asian Pac. J. Cancer Prev. 15 (2014) 551-560.
5. B.R.R. de Mattos, M.P.G. Garcia, J.B. Nogueira, L.N. Paiatto, C.G. Albuquerque, C.K. Souza, et al., Inflammatory Bowel Disease: An Overview of Immune Mechanisms and Biological Treatments, Mediators of Inflammation. 2015 (2015), 493012.
6. C.-T. Xu, S.-Y. Meng, B.-R. Pan, Drug therapy for ulcerative colitis, World J. Gastroenterol. 10 (2004) 2311-2317.
7. S. Periasamy, D.-Z. Hsu, V.R.M. Chandrasekaran, M.-Y. Liu, Sesame oil accelerates healing of 2, 4, 6-Trinitrobenzenesulfonic acid-induced acute colitis by attenuating inflammation and fibrosis, J. Parenter. Enter. Nutr. 37 (5) (2013) 674-682.
8. A.K. Pandurangan, N. Mohebali, M.E. Norhaizan, C.Y. Looi, Gallic acid attenuatesdextran sulfate sodium-induced experimental colitis in BALB/c mice, Drug Des. Devel, Ther. 9 (2015) 3923-3934.
9. Y. Li, Y. Tian, W. Zhu, J. Gong, W. Zhang, C. Yu, et al., Triptolide induces suppressor of cytokine signaling-3 expression and promotes lamina propria mononuclear cells apoptosis in Crohn's colitis, Int. Immunopharmacol. 16 (2013) 268-274.
10. D.E. Levy, C.K. Lee, What does Stat3 do? J. Clin. Invest. 109 (2002) 1143-1148.
11. J.V. Alvarez, D.A. Frank, Genome-wide analysis of STAT target genes: elucidating the mechanism of STAT-mediated oncogenesis, Cancer Biol. Ther. 3 (2004) 1045-1050.
12. D.R. Hodge, E.M. Hurt, W.L. Farrar, The role of IL-6 and STAT3 in inflammation and cancer, Eur. J. Cancer 41 (2005) 2502-2512.
13. R. Atreya, M. Neurath, Signaling molecules: The pathogenic role of the IL-6/STAT-3 trans signaling pathway in intestinal inflammation and in colonic cancer, Curr. Drug Targets 9 (2008) 369-374.
14. C.A. Anderson, G. Boucher, C.W. Lees, A. Franke, M. D'Amato, K.D. Taylor, et al., Metaanalysis identifies 29 additional ulcerative colitis risk loci, increasing the number of confirmed associations to 47, Nat. Genet. 43 (2011) 246-252.
15. M.F. Neurath, S. Finotto, IL-6 signaling in autoimmunity, chronic inflammation and inflammation-Associated cancer, Cytokine Growth Factor Rev. 22 (2011) 83-89.
16. R. Atreya, J. Mudter, S. Finotto, J. Möllberg, T. Jostock, S. Wirtz, et al., Blockade of interleukin 6 trans signaling suppresses T-cell resistance against apoptosis in chronic intestinal inflammation: evidence in Crohn disease and experimental colitis in vivo, Nat. Med. 6 (2000) 583-588.
17. S. Madlener, C. Illmer, Z. Horvath, P. Saiko, A. Losert, I. Herbacek, et al., Gallic acid inhibits ribonucleotide reductase and cyclooxygenases in human HL-60 promyelocytic leukemia cells, Cancer Lett. 245 (2007) 156-162.
18. M. Xie, B. Hu, Y. Wang, X. Zeng, Grafting of gallic acid onto chitosan enhances antioxidant activities and alters rheological properties of the copolymer, J. Agric. Food Chem. 62 (2014) 9128-9136.
19. C.-Y. Hsiang, Y.-C. Hseu, Y.-C. Chang, K.S. Kumar, T.-Y. Ho, H.-L. Yang, Toona sinensis and its major bioactive compound gallic acid inhibit LPS-induced inflammation in nuclear factor-κB transgenic mice as evaluated by in vivo bioluminescence imaging, Food Chem. 136 (2013) 426-434.
20. K. Ramkumar, R. Vijayakumar, P. Vanitha, N. Suganya, C. Manjula, P. Rajaguru, et al., Protective effect of gallic acid on alloxan-induced oxidative stress and osmotic fragility in rats, Hum. Exp. Toxicol. 33 (2014) 638-649.
21. H.-H. Ho, C.-S. Chang, W.-C. Ho, S.-Y. Liao, W.-L. Lin, C.-J. Wang, Gallic acid inhibits gastric cancer cells metastasis and invasive growth via increased expression of RhoB, downregulation of AKT/small GTPase signals and inhibition of NF-κB activity, Toxicol. Appl. Pharmacol. 266 (2013) 76-85.
22. S. Ma, L. Lv, Q. Lu, Y. Li, F. Zhang, Gallic acid attenuates dimethylnitrosamine-induced acute liver injury in mice through Nrf2-mediated induction of heme oxygenase-1 and glutathione-s-Transferase alpha 3, Med. Chem. 4 (2014) 663-669.
23. Y.J. Chen, L.S. Chang, Gallic acid downregulates matrix metalloproteinase-2 (MMP-2) and MMP-9 in human leukemia cells with expressed Bcr/Abl, Mol. Nutr. Food Res. 56 (2012) 1398-1412.
24. Y.-C. Chia, R. Rajbanshi, C. Calhoun, R.H. Chiu, Anti-neoplastic effects of gallic acid, a major component of Toona sinensis leaf extract, on oral squamous carcinoma cells, Molecules 15 (2010) 8377-8389.
25. R. Ito, M. Kita, M. Shin-Ya, T. Kishida, A. Urano, R. Takada, et al., Involvement of IL-17A in the pathogenesis of DSS-induced colitis in mice, Biochem. Biophys. Res. Commun. 377 (2008) 12-16.
26. Y. Li, C. Yu, W.-m. Zhu, Y. Xie, X. Qi, N. Li, et al., Triptolide ameliorates IL-10-deficient mice colitis by mechanisms involving suppression of IL-6/STAT3 signaling pathway and down-regulation of IL-17, Mol. Immunol. 47 (2010) 2467-2474.
27. K. Suzuki, H. Ota, S. Sasagawa, T. Sakatani, T. Fujikura, Assay method for myeloperoxidase in human polymorphonuclear leukocytes, Anal. Biochem. 132 (1983) 345-352.
28. A.K. Pandurangan, Z. Saadatdoust, H. Hamzah, A. Ismail, Dietary cocoa protects against colitis-Associated cancer by activating the Nrf2/Keap1 pathway, Biofactors 41 (2015) 1-14.
29. A.K. Pandurangan, S. Ismail, Z. Saadatdoust, N.M. Esa, Allicin alleviates Dextran Sodium Sulfate-(DSS-) induced ulcerative colitis in BALB/c mice, Oxidative Med. Cell. Longev. 2015 (2015).
30. F. Tanaka, K. Tominaga, M. Ochi, T. Tanigawa, T. Watanabe, Y. Fujiwara, et al., Exogenous administration of mesenchymal stem cells ameliorates dextran sulfate sodium-induced colitis via anti-inflammatory action in damaged tissue in rats, Life Sci. 83 (2008) 771-779.
31. M. Islam, T. Murata, M. Fujisawa, R. Nagasaka, H. Ushio, A. Bari, et al., Anti-inflammatory effects of phytosteryl ferulates in colitis induced by dextran sulphate sodium in mice, Br. J. Pharmacol. 154 (2008) 812-824.
32. E. Pikarsky, R.M. Porat, I. Stein, R. Abramovitch, S. Amit, S. Kasem, et al., NF-κB functions as a tumour promoter in inflammation-Associated cancer, Nature 431 (2004) 461-466.
33. J.K. Kundu, Y.-J. Surh, Inflammation: gearing the journey to cancer, Mutat. Res. Rev. Mutat. Res. 659 (2008) 15-30.
34. H.-L. Yang, S.-C. Chen, K. Senthil Kumar, K.-N. Yu, P.-D. Lee Chao, S.-Y. Tsai, et al., Antioxidant and anti-inflammatory potential of hesperetin metabolites obtained from hesperetin-Administered rat serum: An ex vivo approach, J. Agric. Food Chem. 60 (2011) 522-532.
35. A.K. Pandurangan, S.A.S. Kumar, P. Dharmalingam, S. Ganapasam, Luteolin, a bioflavonoid inhibits azoxymethane-induced colon carcinogenesis: involvement of iNOS and COX-2, Pharmacogn. Mag. 10 (2014) S306.
36. D. Rachmilewitz, J. Stamler, D. Bachwich, F. Karmeli, Z. Ackerman, D. Podolsky, Enhanced colonic nitric oxide generation and nitric oxide synthase activity in ulcerative colitis and Crohn's disease, Gut 36 (1995) 718-723.
37. H. Kimura, S. Miura, T. Shigematsu, N. Ohkubo, Y. Tsuzuki, I. Kurose, et al., Increased nitric oxide production and inducible nitric oxide synthase activity in colonicmucosa of patients with active ulcerative colitis and Crohn's disease, Dig. Dis. Sci. 42 (1997) 1047-1054.
38. I.I. Singer, D.W. Kawka, S. Scott, J.R. Weidner, R.A. Mumford, T.E. Riehl, et al., Expression of inducible nitric oxide synthase and nitrotyrosine in colonic epithelium in inflammatory bowel disease, Gastroenterology 111 (1996) 871-885.
39. X. Ding, Y. Hiraku, N. Ma, T. Kato, K. Saito, M. Nagahama, et al., Inducible nitric oxide synthase-dependent DNA damage in mouse model of inflammatory bowel disease, Cancer Sci. 96 (2005) 157-163.
40. R.R. Ghatule, M.K. Gautam, S. Goel, A. Singh, V.K. Joshi, R.K. Goel, Protective effects of Aegle marmelos fruit pulp on 2, 4, 6-Trinitrobenzene sulfonic acid-induced experimental colitis, Pharmacogn. Mag. 10 (2014) S147.
41. P. Roberts, K. Morgan, R. Miller, J. Hunter, S. Middleton, Neuronal COX-2 expression in humanmyenteric plexus in active inflammatory bowel disease, Gut 48 (2001) 468-472.
42. D. Wang, R.N. DuBois, The role of COX-2 in intestinal inflammation and colorectal cancer, Oncogene 29 (2010) 781-788.
43. W.-W. Lin, M. Karin, A cytokine-mediated link between innate immunity, inflammation, and cancer, J. Clin. Invest. 117 (2007) 1175.
44. J. Bollrath, T.J. Phesse, V.A. von Burstin, T. Putoczki, M. Bennecke, T. Bateman, et al., gp130-mediated Stat3 activation in enterocytes regulates cell survival and cellcycle progression during colitis-Associated tumorigenesis, Cancer Cell 15 (2009) 91-102.
45. E. Degagné, A. Pandurangan, P. Bandhuvula, A. Kumar, A. Eltanawy, M. Zhang, et al., Sphingosine-1-phosphate lyase downregulation promotes colon carcinogenesis through STAT3-Activated microRNAs, J. Clin. Invest. 124 (2014) 5368.
46. S. Kim, T.O. Keku, C. Martin, J. Galanko, J.T. Woosley, J.C. Schroeder, et al., Circulating levels of inflammatory cytokines and risk of colorectal adenomas, Cancer Res. 68 (2008) 323-328.
47. X. Han, D. Sosnowska, E.L. Bonkowski, L.A. Denson, Growth hormone inhibits signal transducer and activator of transcription 3 activation and reduces disease activity in murine colitis, Gastroenterology 129 (2005) 185-203.
48. A. Bai, P. Hu, J. Chen, X. Song, W. Chen, W. Peng, et al., Blockade of STAT3 by antisense oligonucleotide in TNBS-induced murine colitis, Int. J. Color. Dis. 22 (2007) 625-635.
49. M. Marín, R.M. Giner, J.-L. Ríos, M.C. Recio, Intestinal anti-inflammatory activity of ellagic acid in the acute and chronic dextrane sulfate sodium models of mice colitis, J. Ethnopharmacol. 150 (2013) 925-934.